Ikarian Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ikarian Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Buy	+117,500	New	+$1.82M	0.23%	88
2025 Q1	–	Sell	-201,187	Closed	-$760K	–	167
2024 Q4	$760K	Sell	201,187 -73,364	-27%	-$345K	0.1%	119
2024 Q3	$890K	Hold	274,551	–	–	0.12%	101
2024 Q2	$522K	Sell	274,551 -56,900	-17%	-$110K	0.09%	93
2024 Q1	$941K	Sell	331,451 -546,049	-62%	-$7.14M	0.1%	107
2023 Q4	$12.9M	Buy	+877,500	New	+$13.4M	1.21%	25
2023 Q2	–	Sell	-10,000	Closed	-$293K	–	131
2023 Q1	$293K	Buy	+10,000	New	+$347K	0.07%	102
2022 Q3	–	Sell	-246,554	Closed	-$6.15M	–	109
2022 Q2	$4.75M	Sell	246,554 -150,100	-38%	-$1.78M	0.87%	40
2022 Q1	$5.1M	Buy	+396,654	New	+$8.96M	0.67%	41

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ikarian Capital's AMLX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 117,500 shares worth $2.11M. The stake represents 0.23% of the portfolio and ranks #88 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in AMLX as recently as Q4 2024.

Ikarian Capital first reported a position in AMLX in Q1 2022 and has held it in 9 quarters since. The position peaked at $12.9M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Ikarian Capital held 117,500 shares of Amylyx Pharmaceuticals worth $2.11M as of Q2 2026.
Amylyx Pharmaceuticals was a new Ikarian Capital position in Q2 2026.
Amylyx Pharmaceuticals made up 0.23% of Ikarian Capital's portfolio in Q2 2026, its #88 holding.
Ikarian Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
Ikarian Capital's Amylyx Pharmaceuticals position peaked at $12.9M in Q4 2023.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.